Optimized antiretroviral therapy: the role of therapeutic drug monitoring and pharmacogenomics.

about

Therapeutic drug monitoring of protease inhibitors and efavirenz in HIV-infected individuals with active substance-related disorders.HIV entry inhibitors: a new generation of antiretroviral drugs.Pharmacogenomics of CYP3A: considerations for HIV treatment.

P2860

Q35061983-2CD8A3A7-0EBE-4022-900F-8B794681D5BD Q36262437-60A3B411-CAEE-4600-B6F4-F86473768980 Q37419542-13FC4883-436B-493C-B0B8-362B7E3A2F61

P2860

Optimized antiretroviral therapy: the role of therapeutic drug monitoring and pharmacogenomics.

Item

http://www.wikidata.org/entity/Q35917140

description

2003 nî lūn-bûn

@nan

2003年の論文

@ja

2003年論文

@yue

2003年論文

@zh-hant

2003年論文

@zh-hk

2003年論文

@zh-mo

2003年論文

@zh-tw

2003年论文

@wuu

2003年论文

@zh

2003年论文

@zh-cn

name

Optimized antiretroviral thera ...... nitoring and pharmacogenomics.

@ast

Optimized antiretroviral thera ...... nitoring and pharmacogenomics.

@en

type

Item

label

Optimized antiretroviral thera ...... nitoring and pharmacogenomics.

@ast

Optimized antiretroviral thera ...... nitoring and pharmacogenomics.

@en

prefLabel

Optimized antiretroviral thera ...... nitoring and pharmacogenomics.

@ast

Optimized antiretroviral thera ...... nitoring and pharmacogenomics.

@en

P1476

Optimized antiretroviral thera ...... nitoring and pharmacogenomics.

@en

P2093

Rolf P G van Heeswijk

http://www.w3.org/2001/XMLSchema#string

P2860

Hollow-fiber unit evaluation of a new human immunodeficiency virus type 1 protease inhibitor, BMS-232632, for determination of the linked pharmacodynamic variable.

Pharmacokinetic and pharmacodynamic study of the human immunodeficiency virus protease inhibitor amprenavir after multiple oral dosing

Virtual inhibitory quotient predicts response to ritonavir boosting of indinavir-based therapy in human immunodeficiency virus-infected patients with ongoing viremia.

Considering genetic profiles in functional studies of immune responsiveness to HIV-1.

Critical issues in therapeutic drug monitoring of antiretroviral drugs.

Pharmacokinetic-pharmacodynamic analysis of lopinavir-ritonavir in combination with efavirenz and two nucleoside reverse transcriptase inhibitors in extensively pretreated human immunodeficiency virus-infected patients.

Genotypic inhibitory quotient as predictor of virological response to ritonavir-amprenavir in human immunodeficiency virus type 1 protease inhibitor-experienced patients

Genetic polymorphisms of the human MDR1 drug transporter.

Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo

CC chemokine receptor 5 delta32 and CC chemokine receptor 2 64I polymorphisms do not influence the virologic and immunologic response to antiretroviral combination therapy in human immunodeficiency virus type 1-infected patients.

P304

75-81

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1586/14787210.1.1.75

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2003-06-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

15482103

http://www.w3.org/2001/XMLSchema#string

P921

pharmacogenomics

antiretroviral drug

Optimized antiretroviral therapy: the role of therapeutic drug monitoring and pharmacogenomics.

about

P2860

P2860

Optimized antiretroviral therapy: the role of therapeutic drug monitoring and pharmacogenomics.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P698

P921

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P698

P921